EntryPoint Capital’s Theravance Biopharma TBPH Stock Holding History

EntryPoint Capital’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-49,739	Closed	-$807K	–	959
2026 Q1	$807K	Buy	49,739 +15,164	+44%	+$268K	0.24%	91
2025 Q4	$647K	Buy	34,575 +4,320	+14%	+$71.7K	0.25%	91
2025 Q3	$442K	Buy	30,255 +2,351	+8%	+$29.7K	0.17%	215
2025 Q2	$308K	Buy	+27,904	New	+$271K	0.15%	263

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

EntryPoint Capital's TBPH Position: Q2 2026 in Review

EntryPoint Capital sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 49,739 shares — an estimated $807K sold.

EntryPoint Capital first reported a position in TBPH in Q2 2025 and held it in 4 quarters. The position peaked at $807K in Q1 2026. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

EntryPoint Capital reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
EntryPoint Capital sold 49,739 Theravance Biopharma shares in Q2 2026, an estimated $807K.
EntryPoint Capital first reported a position in Theravance Biopharma in Q2 2025 and held it in 4 quarters.
EntryPoint Capital's Theravance Biopharma position peaked at $807K in Q1 2026.
181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.